WARNING: FETAL TOXICITY When pregnancy is detected, discontinue MICARDIS HCT as soon as possible [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)]. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1)].
WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. (5.1, 8.1) Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1, 8.1)
Use: Labeled indications
- MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure.
- MICARDIS HCT is not indicated for initial therapy
Full indications and usage US FDA label
1 INDICATIONS AND USAGE MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs.
There are no controlled trials demonstrating risk reduction with MICARDIS HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals.
For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits.
The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit.
Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease).
These considerations may guide selection of therapy [see Clinical Studies (14)]. MICARDIS HCT is not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. MICARDIS HCT may be used alone or in combination with other antihypertensive agents. MICARDIS HCT is a combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure.
Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1) MICARDIS HCT is not indicated for initial therapy (1)
Contraindications
4 CONTRAINDICATIONS MICARDIS HCT is contraindicated: In patients who are hypersensitive to any component of this product [see Warnings and Precautions (5.5)]. In patients with anuria. For co-administration with aliskiren in patients with diabetes [see Drug Interactions (7.4)]. Hypersensitivity to telmisartan or any component (4) Anuria (4) Co-Administration with aliskiren in patients with diabetes (4)
US FDA labelDosing: Adult
- Usual starting dose is 80 mg/12.5 mg once daily (2.1)
- Titrate up to 160 mg/25 mg as needed (2.1)
- Initiate patients with biliary obstructive disorders or hepatic insufficiency at 40 mg/12.5 mg (2.2)
2.1 Dosing Information
2.1 Dosing Information Initiate a patient whose blood pressure is not adequately controlled with telmisartan monotherapy 80 mg on MICARDIS HCT, 80 mg/12.5 mg orally once daily. Dose can be titrated up to 160 mg/25 mg after 2 to 4 weeks, if necessary. Initiate a patient whose blood pressure is not adequately controlled by 25 mg once daily of hydrochlorothiazide, or is controlled but who experiences hypokalemia with this regimen on MICARDIS HCT 80 mg/12.5 mg once daily.
Dose can be titrated up to 160 mg/25 mg after 2 to 4 weeks, if necessary. Patients titrated to the individual components (telmisartan and hydrochlorothiazide) may instead receive the corresponding dose of MICARDIS HCT. MICARDIS HCT may be administered with other antihypertensive drugs.
2.2 Dose Adjustment for Hepatic Impairment
2.2 Dose Adjustment for Hepatic Impairment Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. MICARDIS HCT tablets are not recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
2.3 Important Administration Instructions
2.3 Important Administration Instructions MICARDIS HCT tablets should not be removed from blisters until immediately before administration.
Dosing: Altered kidney function
Renal Insufficiency: Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
2.2 Dose Adjustment for Hepatic Impairment Initiate patients with biliary obstructive disorders or hepatic insufficiency under close medical supervision using the 40 mg/12.5 mg combination. MICARDIS HCT tablets are not recommended for patients with severe hepatic impairment [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use Safety and effectiveness of MICARDIS HCT in pediatric patients have not been established. Neonates with a history of in utero exposure to MICARDIS HCT: If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as means of reversing hypotension and/or substituting for disordered renal function.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use In the controlled clinical trials (n=1017), approximately 20% of patients treated with telmisartan/hydrochlorothiazide were 65 years of age or older, and 5% were 75 years of age or older. No overall differences in effectiveness and safety of telmisartan/hydrochlorothiazide were observed in these patients compared to younger patients.
Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function and of concomitant diseases or other drug therapy.
Administration
2.3 Important Administration Instructions MICARDIS HCT tablets should not be removed from blisters until immediately before administration.
US FDA labelDosage forms
Philippines
- Tablet: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg
- Film-coated tablet: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg
- Uncoated bilayered tablet: 40 mg/12.5 mg, 80 mg/12.5 mg
Registered products in the Philippines
101 products registered with the Food and Drug Administration (FDA) Philippines list Hydrochlorothiazide + Telmisartan as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Telmisartan + Hydrochlorthiazide (2 products). Products registered under these spellings are included in the table and marked.
All registered products101
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Actarb HTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu Blister Pack x 3's x 10's Tablets (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Sun Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4490-05 | Jun 18, 2028 | |
Actarb-HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10's tablets (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Sun Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4489-09 | Jun 18, 2028 | |
AjezideTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Actavis Ltd.Malta | AJ Research & Pharma, Inc.Importer: AJ Research & Pharma | DR-XY47895 | Apr 4, 2027 | |
ARB PlusTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg Film-Coated TabletAlu strip pack x 10's (box of 30's) | RxVAT-exempt | Corona Remedies Private LimitedIndia | Verheilen PharmaceuticalsImporter: Farma Iberica CorporationTrader: Farma Iberica S.L. | DR-XY47702 | Jan 31, 2027 | |
Emzart PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg Film-Coated TabletAlu/ALu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Ürünleri Ilaçlari San. Ve Tic. A.S.Turkey | Emcure Pharma Philippines Inc.Importer: Sandoz Philippines Corporation | DRP-11408-01 | Mar 10, 2027 | |
Emzart-H 40Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc. | DRP-14527-01 | Oct 2, 2028 | |
Emzart-H 80Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Emcure Pharma Philippines, Inc.Importer: AMB HK Enterprises, Inc. | DRP-14526-01 | Oct 2, 2028 | |
IpstalTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | I.P.S. Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4489-02 | Jun 18, 2028 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletOPA/Alu/PVC-Alu blister pack x 7's (Box of 28's) | RxVAT-exempt | KRKA, D.D., Novo MestoSlovenia | Unilab, Inc. | DRP-12699 | Sep 23, 2027 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 40mg/12.5mg TabletAlu-Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8454-01 | Jun 14, 2029 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletBlister pack x 7s | RxVAT-exempt | KRKA, D.D., Novo MestoSlovenia | Unilab, Inc. | DRP-12700 | Sep 23, 2027 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8455-01 | Jun 14, 2029 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | UNILAB, Inc.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-9984-01 | Jun 14, 2029 | |
Merit PlusTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu-Alu/OPA/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Krka, d. d., Novo mestoSlovenia | UNILAB, Inc. | DRP-12776 | Oct 11, 2027 | |
Mezartel-HTelmisartan + Hydrochlorothiazide | 40 mg / 12.5mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Macter International Ltd.Pakistan | Amson PharmaceuticalsImporter: Sahar International Trading, Inc. | DRP-7721-01 | Jul 20, 2031 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Pharma GmbH & Co. KGGermany | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7622 | Mar 17, 2029 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Hellas Single Member S.A.Greece | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-9600 | Mar 25, 2031 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 80 mg / 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Pharma GmbH & Co. KGGermany | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7621 | Jul 2, 2029 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Boehringer Ingelheim Pharma GmbH & Co. KGGermany | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-7571 | Mar 17, 2029 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Hellas Single Member S.A.Greece | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-9599 | Mar 25, 2031 | |
Micardis PlusTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Boehringer Ingelheim Hellas Single Member S.A.Greece | Importer: Boehringer Ingelheim (Philippines), Inc. | DRP-9598 | Mar 25, 2031 | |
Micargen PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Alternative Platform Exchange, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8454-03 | Jun 14, 2029 | |
Micavid PlusTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Hovid Inc.Trader: Hovid Berhad | DRP-16794 | Jul 11, 2030 | |
Micavid PlusTelmisartan + Hydrochlorothiazide | 80 mg/ 12.5 mg TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Hovid Inc.Trader: Hovid Bhd. | DRP-16701 | Jun 23, 2030 | |
Misar-HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Orange Biotec Inc. | DRP-3199 | Aug 23, 2031 | |
Mizar Plus 80Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack by 10's (Box of 30's) | RxVAT-exempt | Hiral Labs LimitedIndia | Macropharma CorporationImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-11561-01 | Mar 30, 2027 | |
Mycartan PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8454-02 | Jun 14, 2029 | |
Mycartan PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc. | DRP-9984-02 | Jun 14, 2029 | |
Mycartan PlusTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Amediqo Phils., Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8455-02 | Jun 14, 2029 | |
NoneTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4489-01 | Jun 18, 2028 | |
NoneTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-4489-08 | Jun 18, 2028 | |
NoneTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4489-10 | Jun 18, 2028 | |
NoneTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8454 | Jun 14, 2029 | |
NoneTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-4490-01 | Jun 18, 2028 | |
NoneTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | MEDINOVA PHARMACEUTICAL INC. | DRP-9984 | Jun 14, 2029 | |
NoneTelmisartan + Hydrochlorothiazide | 80 mg/25 mg Film-coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari San. Ve. Tic. A.S.Turkey | Sandoz Philippines Corporation | DRP-9479 | Jan 25, 2031 | |
NoneTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu-Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | ONESOURCE PHARMA SOLUTIONS, INC. | DRP-7911 | Jul 6, 2028 | |
NoneTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | RITEMED PHILS., INC.Importer: MEDINOVA PHARMACEUTICAL INC. | DRP-8455 | Jun 14, 2029 | |
Oratel-HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Suhitas Pharmaceuticals, Inc.Importer: Orange Biotec, Inc. | DRP-3199-04 | Aug 23, 2031 | |
Telarb PlusTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | The Cathay YSS Distributors Co., Inc. | DR-XY49104 | Jun 3, 2029 | |
Telarb PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Orange Biotec Inc. | DRP-3199-08 | Aug 23, 2031 | |
Telarb PlusTelmisartan + Hydrochlorothiazide | 80 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | The Cathay YSS Distributors Co., Inc. | DR-XY49105 | Jun 3, 2029 | |
Telarb PlusTelmisartan + Hydrochlorothiazide | 80 mg/ 25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare Limited.India | The Cathay YSS Distributors Co., Inc. | DR-XY49103 | Jun 3, 2029 | |
Telatraz PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alembic Pharmaceuticals LimitedIndia | Natrapharm Inc. | DR-XY49218 | Sep 20, 2029 | |
Telatraz PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alembic Pharmaceuticals LimitedIndia | Natrapharm Inc. | DR-XY49217 | Sep 20, 2029 | |
Telatraz PlusTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alembic Pharmaceuticals LimitedIndia | Natrapharm Inc. | DR-XY49216 | Sep 20, 2029 | |
TelchorTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Britton Distributions, Inc.Importer: Orange Biotec Inc. | DRP-3199-10 | Aug 23, 2031 | |
Telday 40 HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | TORRENT PHARMACEUTICALS LTDIndia | TORRENT PHARMA PHILIPPINES, INC. | DR-XY42407 | Aug 8, 2028 | |
Telday 80 HTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | TORRENT PHARMACEUTICALS LTD.India | TORRENT PHARMA PHILIPPINES, INC. | DR-XY42408 | Aug 8, 2028 | |
Telday H 40/12.5Telmisartan + Hydrochlorothiazide | 40 mg /12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 Tablets (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4489-06 | Jun 18, 2028 | |
Telday H 80/12.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 Tablets (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Torrent Pharma Philippines, Inc.Importer: Ambica International Corporation | DRP-4490-04 | Jun 18, 2028 | |
Telday H 80/25Telmisartan + Hydrochlorothiazide | 80mg/25mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Torrent Pharma Philippines, Inc. | DR-XY47476 | Nov 16, 2026Past listed date | |
Teldra PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-17660-01 | Feb 12, 2031 | |
Telgrand-HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Grandis Pharma IncorporatedImporter: Pharmakon Biotec Inc. | DRP-15318-01 | Jun 18, 2029 | |
Teli HTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Cadila Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-7755 | Mar 21, 2028 | |
TeliGen HCTTelmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, IncPhilippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-18266 | Jun 4, 2031 | |
Telmart DuoTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Macropharma CorporationImporter: Medinova Pharmaceutical Inc. | DRP-8454-04 | Jun 14, 2029 | |
Telmart DuoTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Evertogen Life Sciences LimitedIndia | Macropharma CorporationImporter: Medinova Pharmaceutical Inc. | DRP-9984-03 | Jun 14, 2029 | |
Telmart HCT 40Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30’s) | RxVAT-exempt | Hiral Labs LimitedIndia | Macropharma CorporationImporter: Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-13271-01 | Jan 17, 2028 | |
Telmi HCTTelmisartan + Hydrochlorothiazide | 40mg/12.5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Ajanta Pharma Philippines Inc.Importer: Ajanta Pharma Philippines Inc.. | DR-XY48370 | Sep 22, 2027 | |
Telmi HCTTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ajanta Pharma LimitedIndia | Importer: Ajanta Pharma Philippines Inc.. | DR-XY48039 | May 25, 2027 | |
Telmibet-PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc. | DRP-3199-06 | Aug 23, 2031 | |
Telmidec-HCTTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | HLM Pharmaceutical Inc.Importer: Orange Biotec Inc. | DRP-3199-03 | Aug 23, 2031 | |
Telmidin PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Medchoice CNS Pharma CorporationImporter: Ambica International Corporation | DRP-4489-04 | Jun 18, 2028 | |
Telmifast-HTelmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Ravian Life Science Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15318-02 | Jun 18, 2029 | |
Telmiheart Plus 52.5Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-4489-03 | Jun 18, 2028 | |
Telmiheart Plus 92.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-4490-02 | Jun 18, 2028 | |
TELMIHYDROZET 40Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | 777 RED PHARMA INC.Importer: Nelpa Lifesciences, Inc. | DRP-17421-01 | Dec 19, 2030 | |
Telmirin PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Corbridge Group Phils., Inc.Importer: Orange Biotec Inc. | DRP-3199-05 | Aug 23, 2031 | |
Telmirx-HCTZTelmisartan/Hydrochlorothiazide | 40mg/12.5mg Uncoated Bilayered TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc.Trader: 20260731090220 | DRP-14527 | Oct 2, 2028 | |
Telmirx-HCTZTelmisartan/Hydrochlorothiazide | 80mg/12.5mg Uncoated Bilayered TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc.Trader: N/A | DRP-14526 | Oct 2, 2028 | |
Telmirx-HCTZTelmisartan+Hydrochlorothiazide | 80mg/25mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Globela Pharma Private LimitedIndia | AMB HK Enterprises Inc. | DRP-14525 | Oct 2, 2028 | |
Telmisaph-80H12.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-17423 | Dec 19, 2030 | |
Telmisar PlusTelmisartan + Hydrochlorothiazide | 40mg/12.5mg Film-Coated TabletAlu-Alu Blister Pack X 10's (Box of 30'S) | RxVAT-exempt | Mediwin Pharmaceuticals, IncIndia | Euroasia Pharmaceuticals, IncTrader: Tunic Healthcare | DRP-11014 | Jun 11, 2030 | |
Telmistal H 52.5Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack of 3's x 10 tablets Box of 30's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4489 | Jun 18, 2028 | |
Telmistal H 92.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's x 10 tablets (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-4490 | Jun 18, 2028 | |
Telmisur HCT 40Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International Inc. | DRP-17243 | Oct 24, 2030 | |
Telmisur HCT 80Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International Inc. | DRP-17242 | Oct 24, 2030 | |
Telocar PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3’s x 10 Tablets (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Endure Medical, Inc.Importer: Ambica International Corporation | DRP-4489-07 | Jun 18, 2028 | |
Telsar HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAluminum Strip x 10's (Box of 30's) | RxVAT-exempt | Unichem Laboratories LimitedIndia | Healol Pharma Corporation | DRP-11167 | Aug 29, 2028 | |
Telsitan-HTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 14's (Box of 2's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Macter International Ltd.75700 Pakistan | Sahar International Trading Inc. | DRP-7721 | Jul 20, 2031 | |
80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited-Philippine Branch Office | DRP-10986 | Dec 28, 2026 | ||
80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Intas Pharmaceuticals LimitedIndia | Accord Healthcare Limited-Philippine Branch Office | DRP-10985 | Dec 28, 2026 | ||
Teluvis PlusTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Ürünleri Ilaclari San. Ve Tic. A.S.Turkey | Importer: Sandoz Philippines Corporation | DRP-11409 | Mar 10, 2027 | |
Teluvis PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Ürünleri Ilaclari San. Ve Tic. A.S.Turkey | Importer: Sandoz Philippines Corporation | DRP-11408 | Mar 10, 2027 | |
TelxiblocTelmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 3's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Radbuster Inc.Importer: Ambica International Corporation | DRP-4489-05 | Jun 18, 2028 | |
Telxibloc PlusTelmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 3’s x 10's (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Radbuster Inc.Importer: Ambica International Corporation | DRP-4490-03 | Jun 18, 2028 | |
Telzipar-105Telmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Alwin DMD PharmaceuticalsIndia | Aspar Pharmaceutical Inc. | DRP-18320 | Jun 11, 2031 | |
Telzyd H 40/12.5Telmisartan + Hydrochlorothiazide | 40 mg / 12.5 mg TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Theon Pharmaceuticals Ltd.India | Zydus Healthcare Philippines, Inc.Importer: Orange Biotec Inc. | DRP-3199-02 | Aug 23, 2031 | |
Temtan-H 40Telmisartan + Hydrochlorothiazide | 40 mg/ 12.5 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hiral Labs LimitedIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-13271 | Jan 17, 2028 | |
Temtan-H 80Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Hiral Labs LimitedIndia | Aglobal Care, Inc.Trader: Antila Lifesciences Pvt. Ltd. | DRP-11561 | Mar 30, 2032 | |
Tevex TH 80/12.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | East African (India) OverseasIndia | Ve Pharma Inc.Trader: Vexxa Lifesciences Pvt. Ltd. | DR-XY49427 | Jun 27, 2030 | |
Trelauro-H 40/12.5Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited - Unit VIIIndia | AAA Pharma, Inc. | DR-XY49559 | Oct 20, 2030 | |
Trelauro-H 80/12.5Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited Unit VIIIndia | AAA Pharma, Inc. | DR-XY49575 | Nov 7, 2030 | |
Trelauro-H 80/25Telmisartan + Hydrochlorothiazide | 80 mg/25 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited - Unit VIIIndia | AAA Pharma, Inc. | DR-XY49558 | Oct 20, 2030 | |
Tsartan PlusTelmisartan + Hydrochlorothiazide | 40mg/12.5mg TabletAlu-Alu Blister Pack x 10's (Box of 30' s) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-14147 | Jun 30, 2028 | |
Tsartan PlusTelmisartan + Hydrochlorothiazide | 80mg/12.5mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-14236 | Aug 1, 2028 | |
Tsartan PlusTelmisartan + Hydrochlorothiazide | 80mg/25mg TabletAlu-Alu Blister Pack x 10' s (Box of 30' s) | RxVAT-exempt | Inventia Healthcare LimitedIndia | Orange Biotec Inc. | DRP-14146 | Jun 30, 2028 | |
(no brand name)Telmisartan + Hydrochlorothiazide | 40 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Onesource Pharma Solutions, Inc. | DRP-14139 | Jun 30, 2028 | |
(no brand name)Telmisartan + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The Acme Laboratories LimitedBangladesh | Euro Generics International Phils., Inc. | DR-XY49576 | Nov 17, 2030 | |
(no brand name)Telmisartan + + Hydrochlorothiazide | 80 mg/12.5 mg TabletAlu-Alu Blister Pack x 10s (Box of 30's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Onesource Pharma Solutions, Inc. | DRP-16870 | Aug 1, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS 40 mg/12.5 mg, red and white tablets marked with the Boehringer Ingelheim logo and "H4" 80 mg/12.5 mg, red and white tablets marked with the Boehringer Ingelheim logo and "H8" 80 mg/25 mg, yellow and white tablets marked with the Boehringer Ingelheim logo and "H9" Tablets: 40 mg/12.5 mg, 80 mg/12.5 mg, 80 mg/25 mg (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Avoid fetal or neonatal exposure (5.1)
- Correct volume or salt depletion before initiating therapy. Observe for signs and symptoms of hypotension. (5.2)
- Monitor renal function and potassium in susceptible patients (5.3)
- Observe for clinical signs of fluid or electrolyte imbalance (5.4)
- Hypersensitivity Reaction (5.5)
- Acute Myopia and Secondary Angle-Closure Glaucoma (5.6)
5.1 Fetal Toxicity
5.1 Fetal Toxicity Telmisartan Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.
When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. Hydrochlorothiazide Thiazides cross the placental barrier and appear in cord blood. Adverse reactions include fetal or neonatal jaundice and thrombocytopenia [see Use in Specific Populations (8.1)].
5.2 Hypotension in Volume- or Salt-Depleted Patients
5.2 Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initialization of treatment with MICARDIS HCT. Correct volume or salt depletion prior to administration of MICARDIS HCT.
5.3 Impaired Renal Function
5.3 Impaired Renal Function Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing oliguria, progressive azotemia, or acute renal failure on MICARDIS HCT.
Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on MICARDIS HCT.
5.4 Electrolytes and Metabolic Disorders
5.4 Electrolytes and Metabolic Disorders Drugs, including telmisartan, that inhibit the renin-angiotensin system can cause hyperkalemia, particularly in patients with renal insufficiency, diabetes, or combination use with other angiotensin receptor blockers or ACE inhibitors and the concomitant use of other drugs that raise serum potassium levels [see Drug Interactions (7.1, 7.4)]. Hydrochlorothiazide can cause hypokalemia and hyponatremia.
Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Hypomagnesemia can result in hypokalemia which may be difficult to treat despite potassium repletion. Monitor serum electrolytes periodically. In controlled trials using the telmisartan/hydrochlorothiazide combination treatment, no patient administered 40 mg/12.5 mg, 80 mg/12.5 mg, or 80 mg/25 mg experienced a decrease in potassium ≥1.4 mEq/L, and no patient experienced hyperkalemia.
Hydrochlorothiazide decreases urinary calcium excretion and may cause elevations of serum calcium. Hydrochlorothiazide may alter glucose tolerance and raise serum levels of cholesterol and triglycerides. Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy. Because telmisartan decreases uric acid, telmisartan in combination with hydrochlorothiazide attenuates the diuretic-induced hyperuricemia.
5.5 Hypersensitivity Reaction
5.5 Hypersensitivity Reaction Hydrochlorothiazide Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history [see Contraindications (4)].
5.6 Acute Myopia and Secondary Angle-Closure Glaucoma
5.6 Acute Myopia and Secondary Angle-Closure Glaucoma Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.
Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
5.7 Systemic Lupus Erythematosus
5.7 Systemic Lupus Erythematosus Thiazide diuretics have been reported to cause exacerbation or activation of systemic lupus erythematosus.
5.8 Postsympathectomy Patients
5.8 Postsympathectomy Patients The antihypertensive effects of hydrochlorothiazide may be enhanced in the postsympathectomy patient.
Drug interactions
- Lithium: Risk of lithium toxicity (7.2)
- Non-steroidal anti-inflammatory drugs (NSAIDs): Reduced diuretic, natriuretic, and antihypertensive effects; increased risk of renal impairment (7.3)
- Dual blockade of renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia (7.4)
- Antidiabetic drugs: Dosage adjustment may be required (7.6)
- Cholestyramine and colestipol: Reduced absorption of thiazides (7.7)
7.1 Agents Increasing Serum Potassium
7.1 Agents Increasing Serum Potassium Co-administration of telmisartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
7.2 Lithium
7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported with concomitant use of thiazide diuretics or angiotensin II receptor antagonists, including telmisartan. Monitor lithium levels in patients receiving MICARDIS HCT and lithium.
7.3 Non-Steroidal Anti-Inflammatory
7.3 Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors Telmisartan Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors): In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with ARBs, including telmisartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
The antihypertensive effect of ARBs may be attenuated by NSAIDs. Therefore, monitor renal function and blood pressure periodically in patients receiving MICARDIS HCT and NSAIDs. Hydrochlorothiazide Administration of a non-steroidal anti-inflammatory agent, including a selective COX-2 inhibitor, can reduce the diuretic, natriuretic, and antihypertensive effects of diuretics.
Therefore, when MICARDIS HCT and non-steroidal anti-inflammatory agents including selective COX-2 inhibitors are used concomitantly, observe closely to determine if the desired effect of the diuretic is obtained.
7.4 Dual Blockade of the Renin-Angiotensin-Aldosterone System and Changes in Renal Function
7.4 Dual Blockade of the Renin-Angiotensin-Aldosterone System and Changes in Renal Function Dual blockade of the renin-angiotensin-aldosterone system (RAS) with angiotensin blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and renal impairment. The ONTARGET trial enrolled 25,620 patients ≥55 years old with atherosclerotic disease or diabetes with end-organ damage, randomizing them to telmisartan (ARB) only, ramipril (ACE inhibitor) only, or the combination, and followed them for a median of 56 months.
Patients who received the combination of ARB and ACE inhibitor did not obtain any additional benefit (no additional reduction of risk of cardiovascular death, myocardial infarction, stroke, or hospitalization from heart failure) compared to ARB monotherapy or ACE inhibitor monotherapy, but experienced an increased incidence of renal dysfunction (e.g., acute renal failure) compared with monotherapy groups. In general, avoid combined use of RAS inhibitors.
Closely monitor blood pressure, renal function and electrolytes in patients on MICARDIS HCT and other agents that affect the RAS. Do not co-administer aliskiren with MICARDIS HCT in patients with diabetes. Avoid concomitant use of aliskiren with MICARDIS HCT in patients with renal impairment (GFR <60 mL/min/1.73 m²).
7.5 Digoxin
7.5 Digoxin When telmisartan was co-administered with digoxin, median increases in digoxin peak plasma concentration (49%) and in trough concentration (20%) were observed. Monitor digoxin levels in patients taking concomitant MICARDIS HCT and digoxin.
7.6 Antidiabetic Drugs (Oral Agents and Insulin)
7.6 Antidiabetic Drugs (Oral Agents and Insulin) Dosage adjustment of antidiabetic drugs may be required when co-administered with hydrochlorothiazide.
7.7 Cholestyramine and Colestipol Resins
7.7 Cholestyramine and Colestipol Resins Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins. Stagger the dosage of hydrochlorothiazide and the resin such that hydrochlorothiazide is administered at least 4 hours before or 4 to 6 hours after the administration of the resin.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.
Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Adverse reactions
- The following adverse reactions are discussed elsewhere in labeling: Hypotension [see Warnings and Precautions (5.2)] Renal Impairment [see Warnings and Precautions (5.3)] Electrolytes and Metabolic Disorders [see Warnings and Precautions (5.4)] The most common adverse reactions (≥2% of patients) were upper respiratory tract infection, dizziness, sinusitis, diarrhea, fatigue, influenza-like symptoms, and nausea (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Boehringer Ingelheim Pharmaceuticals, Inc. at (800) 542-6257 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. MICARDIS HCT has been evaluated for safety in more than 1700 patients, including 716 treated for hypertension for longer than 6 months and 420 for more than 1 year.
Adverse reactions have been limited to those that have been previously reported with telmisartan and/or hydrochlorothiazide. Adverse reactions occurring at an incidence of ≥2% in patients treated with telmisartan/hydrochlorothiazide and at a greater rate than in patients treated with placebo, are presented in Table 1 [see Clinical Studies (14)].
Table 1 Adverse Reactions Occurring at an Incidence of ≥2% in Patients Treated with Telmisartan/Hydrochlorothiazide and at a Greater Rate Than in Patients Treated with Placebo* * includes all doses of telmisartan (20 to 160 mg), hydrochlorothiazide (6.25 to 25 mg), and combinations thereof Telmisartan/Hydrochlorothiazide (n = 414) Placebo (n = 74) Telmisartan (n = 209) Hydrochlorothiazide (n = 121) Body as a whole Fatigue 3% 1% 3% 3% Influenza-like symptoms 2% 1% 2% 3% Central/Peripheral nervous system Dizziness 5% 1% 4% 6% Gastrointestinal system Diarrhea 3% 0% 5% 2% Nausea 2% 0% 1% 2% Respiratory system disorder Sinusitis 4% 3% 3% 6% Upper respiratory tract infection 8% 7% 7% 10% Other adverse reactions observed for telmisartan/hydrochlorothiazide were: pain (including back and abdominal), dyspepsia, erythema, vomiting, bronchitis, and pharyngitis. Adverse reactions occurred at approximately the same rates in men and women, older and younger patients, and black and non-black patients.
Telmisartan Other adverse events that have been reported with telmisartan are listed below: Autonomic Nervous System: impotence, increased sweating, flushing Body as a Whole: allergy, fever, leg pain, chest pain Cardiovascular: palpitation, angina pectoris, abnormal ECG, hypertension, peripheral edema Central Nervous System: insomnia, somnolence, migraine, paresthesia, involuntary muscle contractions, hypoesthesia Gastrointestinal: flatulence, constipation, gastritis, dry mouth, hemorrhoids, gastroesophageal reflux, toothache Hepato-biliary: elevations of liver enzymes or serum bilirubin Metabolic: gout, hypercholesterolemia, diabetes mellitus Musculoskeletal: arthritis, arthralgia, leg cramps, myalgia Psychiatric: anxiety, depression, nervousness Resistance Mechanism: infection, abscess, otitis media Respiratory: asthma, rhinitis, dyspnea, epistaxis Skin: dermatitis, eczema, pruritus Urinary: micturition frequency, cystitis Vascular: cerebrovascular disorder Special Senses: abnormal vision, conjunctivitis, tinnitus, earache Hydrochlorothiazide Other adverse events that have been reported with hydrochlorothiazide are listed below: Body as a Whole: weakness Digestive: pancreatitis, jaundice (intrahepatic cholestatic jaundice), sialadenitis, cramping, gastric irritation Hematologic: aplastic anemia, agranulocytosis, leukopenia, hemolytic anemia, thrombocytopenia Hypersensitivity: purpura, photosensitivity, urticaria, necrotizing angiitis (vasculitis and cutaneous vasculitis), fever, respiratory distress including pneumonitis and pulmonary edema, anaphylactic reactions Metabolic: hyperglycemia, glycosuria Musculoskeletal: muscle spasm Nervous System/Psychiatric: restlessness Renal: interstitial nephritis Skin: erythema multiforme including Stevens-Johnson syndrome, exfoliative dermatitis including toxic epidermal necrolysis Special Senses: transient blurred vision, xanthopsia Clinical Laboratory Findings Creatinine, Blood Urea Nitrogen (BUN): Increases in BUN (≥11.2 mg/dL) and serum creatinine (≥0.5 mg/dL) were observed in 2.8% and 1.4%, respectively, of patients with essential hypertension treated with MICARDIS HCT tablets in controlled trials. No patient discontinued treatment with MICARDIS HCT tablets because of an increase in BUN or creatinine [see Warnings and Precautions (5.3)].
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of MICARDIS HCT. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.
Blood and Lymphatic System Disorders: Eosinophilia Cardiac Disorders: Tachycardia Ear and Labyrinth Disorders: Vertigo General Disorders and Administration Site Conditions: Asthenia, edema Hepato-biliary: Abnormal hepatic function/liver disorder Immune System Disorders: Anaphylactic reaction Investigations: Increased CPK Metabolism and Nutrition Disorders: Hypoglycemia (in diabetic patients), hyponatremia Musculoskeletal and Connective Tissue Disorders: Rhabdomyolysis Nervous System Disorders: Headache, syncope Renal and Urinary Disorders: Renal failure, renal impairment including acute renal failure Reproductive System and Breast Disorders: Erectile dysfunction Respiratory, Thoracic and Mediastinal Disorders: Coughing Skin and Subcutaneous Tissue Disorders: Angioedema (with fatal outcome), drug eruption (toxic skin eruption mostly reported as toxicoderma, rash, and urticaria) Vascular Disorder: Orthostatic hypotension Non-melanoma Skin Cancer Hydrochlorothiazide is associated with an increased risk of non-melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for squamous cell carcinoma (SCC) and in white patients taking large cumulative doses.
The increased risk for SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and for white patients taking a cumulative dose of ≥50,000 mg the risk increase was approximately 1 additional SCC case for every 6,700 patients per year.
Adverse reaction frequency tables (US label) US FDA label
| * includes all doses of telmisartan (20 to 160 mg), hydrochlorothiazide (6.25 to 25 mg), and combinations thereof | ||||
| Telmisartan/Hydrochlorothiazide (n = 414) | Placebo (n = 74) | Telmisartan (n = 209) | Hydrochlorothiazide (n = 121) | |
| Body as a whole | ||||
| Fatigue | 3% | 1% | 3% | 3% |
| Influenza-like symptoms | 2% | 1% | 2% | 3% |
| Central/Peripheral nervous system Dizziness | 5% | 1% | 4% | 6% |
| Gastrointestinal system | ||||
| Diarrhea | 3% | 0% | 5% | 2% |
| Nausea | 2% | 0% | 1% | 2% |
| Respiratory system disorder Sinusitis | 4% | 3% | 3% | 6% |
| Upper respiratory tract infection | 8% | 7% | 7% | 10% |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary MICARDIS HCT can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death (see Clinical Considerations). Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
Studies in rats and rabbits with telmisartan showed fetotoxicity only at maternally toxic doses (see Data). When pregnancy is detected, discontinue MICARDIS HCT as soon as possible. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.
In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated maternal and/or embryo/fetal risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, and post-partum hemorrhage).
Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death. Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal adverse reactions Telmisartan Use of drugs that act on the RAS in the second and third trimesters of pregnancy can result in the following: oligohydramnios, reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. In patients taking MICARDIS HCT during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment.
Fetal testing may be appropriate, based on the week of gestation. If oligohydramnios is observed, discontinue MICARDIS HCT, unless it is considered lifesaving for the mother. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe infants with histories of in utero exposure to MICARDIS HCT for hypotension, oliguria, and hyperkalemia.
If oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function [see Use in Specific Populations (8.4)]. Hydrochlorothiazide Thiazides cross the placenta, and use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice, thrombocytopenia, and possible other adverse reactions that have occurred in adults.
Data Animal Data MICARDIS HCT A developmental toxicity study was performed in rats with telmisartan/hydrochlorothiazide doses of 3.2/1.0, 15/4.7, 50/15.6, and 0/15.6 mg/kg/day. Although the two higher dose combinations appeared to be more toxic (significant decrease in body weight gain) to the dams than either drug alone, there did not appear to be an increase in toxicity to the developing embryos.
Telmisartan No teratogenic effects were observed when telmisartan was administered to pregnant rats at oral doses of up to 50 mg/kg/day and to pregnant rabbits at oral doses of up to 45 mg/kg/day. In rabbits, embryo lethality associated with maternal toxicity (reduced body weight gain and food consumption) was observed at 45 mg/kg/day (approximately 12 times the maximum recommended human dose [MRHD] of 80 mg on a mg/m 2 basis).
In rats, maternally toxic (reduced body weight gain and food consumption) telmisartan doses of 15 mg/kg/day (approximately 1.9 times the MRHD on a mg/m 2 basis), administered during late gestation and lactation, were observed to produce adverse effects in neonates, including reduced viability, low birth weight, delayed maturation, and decreased weight gain. The no-observed-effect doses for developmental toxicity in rats and rabbits, 5 and 15 mg/kg/day, respectively, are approximately 0.64 and 3.7 times, respectively, on a mg/m 2 basis, the MRHD of telmisartan (80 mg/day).
Hydrochlorothiazide Studies in which hydrochlorothiazide was administered to pregnant mice and rats during their respective periods of major organogenesis at doses up to 3000 and 1000 mg/kg/day, respectively (about 600 and 400 times the MRHD), provided no evidence of harm to the fetus. Thiazides can cross the placenta, and concentrations reached in the umbilical vein approach those in the maternal plasma.
Hydrochlorothiazide, like other diuretics, can cause placental hypoperfusion. It accumulates in the amniotic fluid, with reported concentrations up to 19 times that in umbilical vein plasma. Use of thiazides during pregnancy is associated with a risk of fetal or neonatal jaundice or thrombocytopenia. Since they do not prevent or alter the course of EPH (Edema, Proteinuria, Hypertension) gestosis (pre-eclampsia), these drugs should not be used to treat hypertension in pregnant women.
The use of hydrochlorothiazide for other indications (e.g., heart disease) in pregnancy should be avoided.
Mechanism of action
12.1 Mechanism of Action MICARDIS HCT MICARDIS HCT is a combination of two drugs with antihypertensive properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan. Telmisartan Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II).
Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland.
Its action is therefore independent of the pathways for angiotensin II synthesis. There is also an AT 2 receptor found in many tissues, but AT 2 is not known to be associated with cardiovascular homeostasis. Telmisartan has much greater affinity (>3,000-fold) for the AT 1 receptor than for the AT 2 receptor. Telmisartan does not inhibit ACE (kininase II) nor does it bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
Blockade of the angiotensin II receptor inhibits the negative regulatory feedback of angiotensin II on renin secretion, but the resulting increased plasma renin activity and angiotensin II circulating levels do not overcome the effect of telmisartan on blood pressure. Hydrochlorothiazide Hydrochlorothiazide is a thiazide diuretic.
Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium salt and chloride in approximately equivalent amounts. Indirectly, the diuretic action of hydrochlorothiazide reduces plasma volume, with consequent increases in plasma renin activity, increases in aldosterone secretion, increases in urinary potassium loss, and decreases in serum potassium.
The renin-aldosterone link is mediated by angiotensin II, so co-administration of an ARB tends to reverse the potassium loss associated with these diuretics. The mechanism of the antihypertensive effect of thiazides is not fully understood.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Telmisartan In normal volunteers, a dose of telmisartan 80 mg inhibited the pressor response to an intravenous infusion of angiotensin II by approximately 90% at peak plasma concentrations with approximately 40% inhibition persisting for 24 hours. Plasma concentration of angiotensin II and plasma renin activity increased in a dose-dependent manner after single administration of telmisartan to healthy subjects and repeated administration to hypertensive patients.
The once-daily administration of up to 80 mg telmisartan to healthy subjects did not influence plasma aldosterone concentrations. In multiple dose studies with hypertensive patients, there were no clinically significant changes in electrolytes (serum potassium or sodium) or in metabolic function (including serum levels of cholesterol, triglycerides, HDL, LDL, glucose, or uric acid).
The antihypertensive effects of telmisartan have been studied in six placebo-controlled clinical trials including a total of 1773 patients with mild to moderate hypertension (diastolic blood pressure of 95 to 114 mmHg), 1031 of whom were treated with telmisartan. Following once-daily administration of telmisartan, the magnitude of blood pressure reduction from baseline after placebo subtraction was approximately (SBP/DBP) 6-8/6 mmHg for 20 mg, 9-13/6-8 mmHg for 40 mg, and 12-13/7-8 mmHg for 80 mg.
Larger doses (up to 160 mg) did not appear to cause a further decrease in blood pressure. The onset of antihypertensive activity occurs within 3 hours, with a maximal reduction by approximately 4 weeks. At doses of 20, 40, and 80 mg, the antihypertensive effect of once-daily administration of telmisartan was maintained for the full 24-hour dose interval.
In 30 hypertensive patients with normal renal function treated for 8 weeks with telmisartan 80 mg or telmisartan 80 mg in combination with hydrochlorothiazide 12.5 mg, there were no clinically significant changes from baseline in renal blood flow, glomerular filtration rate, filtration fraction, renovascular resistance, or creatinine clearance. Hydrochlorothiazide After oral administration of hydrochlorothiazide, diuresis begins within 2 hours, peaks in about 4 hours, and lasts approximately 6 to 12 hours.
Drug Interactions Hydrochlorothiazide Alcohol, barbiturates, or narcotics: Potentiation of orthostatic hypotension may occur. Skeletal muscle relaxants: Possible increased responsiveness to muscle relaxants such as curare derivatives. Corticosteroids, ACTH: Intensified electrolyte depletion, particularly hypokalemia. Pressor amines (e.g., norepinephrine): Possible decreased response to pressor amines but not sufficient to preclude their use.
Pharmacokinetics
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours.
Elimination: Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Terminal half-life and total clearance appear to be independent of dose.
When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.
Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Telmisartan Absorption: Following oral administration, peak concentrations (C max) of telmisartan are reached in 0.5 to 1 hour after dosing. Food slightly reduces the bioavailability of telmisartan, with a reduction in the area under the plasma concentration-time curve (AUC) of approximately 6% with 40 mg and approximately 20% after a 160 mg dose.
MICARDIS HCT can be administered with or without food. The absolute bioavailability of telmisartan is dose dependent. At 40 mg and 160 mg, the bioavailability was 42% and 58%, respectively. The pharmacokinetics of telmisartan with orally administered MICARDIS are nonlinear over the dose range 20 mg to 160 mg, with greater than proportional increases of plasma concentrations (C max and AUC) with increasing doses.
Telmisartan shows bi-exponential decay kinetics with a terminal elimination half-life of approximately 24 hours. Trough plasma concentrations of telmisartan with once-daily dosing are approximately 10% to 25% of peak plasma concentrations. Telmisartan has an accumulation index in plasma of 1.5 to 2.0 upon repeated once-daily dosing.
Distribution: Telmisartan is highly bound to plasma proteins (>99.5%), mainly albumin and α 1 -acid glycoprotein. Plasma protein binding is constant over the concentration range achieved with recommended doses. The volume of distribution for telmisartan is approximately 500 liters, indicating additional tissue binding. Metabolism: Telmisartan is metabolized by conjugation to form a pharmacologically inactive acyl glucuronide; the glucuronide of the parent compound is the only metabolite that has been identified in human plasma and urine.
After a single dose, the glucuronide represents approximately 11% of the measured radioactivity in plasma. The cytochrome P450 isoenzymes are not involved in the metabolism of telmisartan. Elimination: Following either intravenous or oral administration of 14 C-labeled telmisartan, most of the administered dose (>97%) was eliminated unchanged in feces via biliary excretion; only minute amounts were found in the urine (0.91% and 0.49% of total radioactivity, respectively).
Total plasma clearance of telmisartan is >800 mL/min. Terminal half-life and total clearance appear to be independent of dose. Hydrochlorothiazide Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.
At least 61% of the oral dose is eliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk. Specific Populations Telmisartan Renal Insufficiency: Telmisartan is not removed from blood by hemofiltration and is not dialyzable [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].
Hepatic Insufficiency: In patients with hepatic insufficiency, plasma concentrations of telmisartan are increased, and absolute bioavailability approaches 100% [see Use in Specific Populations (8.6)]. Gender: Plasma concentrations of telmisartan are generally 2 to 3 times higher in females than in males. In clinical trials, however, no significant increases in blood pressure response or in the incidence of orthostatic hypotension were found in women.
No dosage adjustment is necessary. Geriatric Patients: The pharmacokinetics of telmisartan do not differ between the elderly and those younger than 65 years of age. Drug Interaction Studies Telmisartan Ramipril: Co-administration of telmisartan 80 mg once daily and ramipril 10 mg once daily to healthy subjects increases steady-state C max and AUC of ramipril 2.3- and 2.1-fold, respectively, and C max and AUC of ramiprilat 2.4- and 1.5-fold, respectively.
In contrast, C max and AUC of telmisartan decrease by 31% and 16%, respectively. When co-administering telmisartan and ramipril, the response may be greater because of the possibly additive pharmacodynamic effects of the combined drugs, and also because of the increased exposure to ramipril and ramiprilat in the presence of telmisartan.
Other Drugs: Co-administration of telmisartan did not result in a clinically significant interaction with acetaminophen, amlodipine, glyburide, simvastatin, hydrochlorothiazide, warfarin, or ibuprofen. Telmisartan is not metabolized by the cytochrome P450 system and had no effects in vitro on cytochrome P450 enzymes, except for some inhibition of CYP2C19.
Telmisartan is not expected to interact with drugs that inhibit cytochrome P450 enzymes; it is also not expected to interact with drugs metabolized by cytochrome P450 enzymes, except for possible inhibition of the metabolism of drugs metabolized by CYP2C19.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Telmisartan + Hydrochlorothiazide 40 mg + 12.5 mg Tablet | ₱19.02–₱23.15Reference ₱19.02 | per tablet | DPRI procurement range |
| 40 mg + 12.5 mg tablet | ₱11.75 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Telmisartan + Hydrochlorothiazide |
| PNF listing | Oral: 40 mg + 12.5 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Micardis HCT · Boehringer Ingelheim Pharmaceuticals, Inc. [US FDA-approved label, version 26, December 31, 2024]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b078dae2-664d-4144-847a-3b9d9b557402
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .

